Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: A trial using equipoise-stratified randomization

Journal of Clinical Psychiatry

Volumn 74, Issue 1, 2013, Pages 10-18

  Jin, Hua ^a,d   Shih, Pei An Betty ^a   Golshan, Shahrokh ^a   Mudaliar, Sunder ^c,d   Henry, Robert ^c,d   Glorioso, Danielle K ^a   Arndt, Stephan ^e   Kraemer, Helena C ^f   Jeste, Dilip V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV-TR; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; PATIENT ASSESSMENT; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SURVIVAL RATE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

EID: 84873840061     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08001     Document Type: Article

References (49)

1. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementiarelated symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69(6):889-898.
2. Jeste DV, Dolder CR. Treatment of non-schizophrenic disorders: focus on atypical antipsychotics. J Psychiatr Res. 2004;38(1):73-103.
3. Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry. 1999;56(9):848-853.
4. Alexopoulos GS, Streim JE, Carpenter D, et al Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(suppl 2):5-99, discussion 100-102, quiz 103-104.
5. McDonald WM, Wermager J. Pharmacologic treatment of geriatric mania. Curr Psychiatry Rep. 2002;4(1):43-50.
6. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv. 2009;60(9):1175-1181.
7. Kamble P, Sherer J, Chen H, et al. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv. 2010;61(2):130-136.
8. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12): 1359-1369.
9. Waterreus A, Morgan VA, Castle D, et al. Medication for psychosis - consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46(8):762-773.
10. Kozarić-Kovacić D, Pivac N, Muck-Seler D, et al. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry. 2005;66(7):922-927.
11. Kozarić-Kovacić D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol. 2007;10(2):253-261.
12. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the US Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry. 2008;69(6):959-965.
13. Viana BM, Prais HA, Nicolato R, et al. Posttraumatic brain injury psychosis successfully treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):233-235 14.
14. D'Agostino B Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:753. 15.
15. IMS Health Incorporated. National Disease and Therapeutic Index. September 2009- September 2011. All Rights Reserved. https://web01.imshealth. com/ndti/ndtilogin.aspx. Accessed November 8, 2012.
16. Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001;35(3):187-191.
17. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118(suppl 2):15S-22S.
18. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45-53.
19. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105(1-3):175-187.
20. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):856-865.
21. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004;71(2-3):195-212.
22. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009; 110(1-3):103-110.
23. Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011;128(1-3):166-170.
24. Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med. 2005;353(12):1286-1288.
25. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101(1-3): 273-286.
26. FDA Public Health Advisory. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171. htm. 2005. Updated March 2, 2010. Accessed October 9, 2012.
27. Schneider LS, Tariot PN, Dagerman KS, et al CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538.
28. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
29. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624-1632.
30. Macpherson H. Pragmatic clinical trials. Complement Ther Med. 2004;12(2-3):136-140.
31. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50(10):792-801
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
33. Jin H, Lanouette NM, Mudaliar S, et al. Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome. J Clin Psychopharmacol. 2009;29(3):210-215.
34. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24(1):97-99.
35. Lieberman JA, Stroup TS, McEvoy JP, et al Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
36. Grundy SM, Hansen B. Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vas Biol. 2004;24(2):e19-e24.
37. Jeste DV, Blazer D, Casey DE, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957-970.
38. Jeste DV, Jin H, Golshan S, et al. Discontinuation of quetiapine from an NIMH-funded trial due to serious adverse events. Am J Psychiatry. 2009;166(8):937-938.
39. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
40. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577-581.
41. Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007; 91(6):1169-1184, x.
42. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8-13.
43. Rathmann W, Haastert B, Icks A, et al. Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: the KORA Survey 2000. Diabetes Care. 2006;29(2):461.
44. Ravaglia G, Forti P, Maioli F, et al. Metabolic syndrome: prevalence and prediction of mortality in elderly individuals. Diabetes Care. 2006;29(11): 2471-2476.
45. Scuteri A, Najjar SS, Morrell CH, et al Cardiovascular Health Study. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care. 2005;28(4):882-887.
46. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3): 356-359.
47. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.
48. Kime P. DoD cracks down on off-label drug use. Army Times. http://www.armytimes.com/news/2012/06/military-dod-cracks-down -on-off-label-seroquel-use-061412w/. Updated June 14, 2012. Accessed October 11, 2012.
49. Ballard C, Hanney ML, Theodoulou M, et al; DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157.